Joint longitudinal and time-to-event models for multilevel hierarchical data
暂无分享,去创建一个
Robert Fox | Michael J Crowther | Margarita Moreno-Betancur | Jeff Hammerbacher | Rory Wolfe | Samuel L Brilleman | Jacqueline Buros Novik | James Dunyak | Nidal Al-Huniti | R. Wolfe | S. Brilleman | M. Crowther | N. Al-Huniti | J. Dunyak | Jacqueline Buros Novik | M. Moreno-Betancur | R. Fox | Jeff Hammerbacher
[1] C. Leung,et al. Impact of Rates of Change of Lamina Cribrosa and Optic Nerve Head Surface Depths on Visual Field Progression in Glaucoma. , 2017, Investigative ophthalmology & visual science.
[2] Eleni-Rosalina Andrinopoulou,et al. Bayesian shrinkage approach for a joint model of longitudinal and survival outcomes assuming different association structures , 2016, Statistics in medicine.
[3] Andrew Gelman,et al. The No-U-turn sampler: adaptively setting path lengths in Hamiltonian Monte Carlo , 2011, J. Mach. Learn. Res..
[4] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[5] John B Carlin,et al. Survival analysis with time‐dependent covariates subject to missing data or measurement error: Multiple Imputation for Joint Modeling (MIJM) , 2018, Biostatistics.
[6] Radford M. Neal. MCMC Using Hamiltonian Dynamics , 2011, 1206.1901.
[7] Dorota Kurowicka,et al. Generating random correlation matrices based on vines and extended onion method , 2009, J. Multivar. Anal..
[8] Keith R Abrams,et al. Joint longitudinal hurdle and time‐to‐event models: an application related to viral load and duration of the first treatment regimen in patients with HIV initiating therapy , 2016, Statistics in medicine.
[9] R. Kolamunnage-Dona,et al. Joint modelling of longitudinal and competing risks data , 2008, Statistics in medicine.
[10] R Henderson,et al. Joint modelling of longitudinal measurements and event time data. , 2000, Biostatistics.
[11] Jeffrey S. Rosenthal,et al. Optimal Proposal Distributions and Adaptive MCMC , 2011 .
[12] Dirk Laurie,et al. Calculation of Gauss-Kronrod quadrature rules , 1997, Math. Comput..
[13] S. Luo,et al. Bayesian hierarchical model for multiple repeated measures and survival data: an application to Parkinson's disease , 2014, Statistics in medicine.
[14] S. Müller,et al. Model Selection in Linear Mixed Models , 2013, 1306.2427.
[15] Anastasios A. Tsiatis,et al. Joint Modeling of Longitudinal and Time-to-Event Data : An Overview , 2004 .
[16] J. Gabry,et al. Bayesian Applied Regression Modeling via Stan , 2016 .
[17] Joseph G Ibrahim,et al. Joint modeling of survival and longitudinal non‐survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group , 2015, Statistics in medicine.
[18] Maria Sudell,et al. Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis , 2016, BMC Medical Research Methodology.
[19] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[20] R. Rosenheck,et al. Joint modelling of longitudinal outcome and interval‐censored competing risk dropout in a schizophrenia clinical trial , 2012, Journal of the Royal Statistical Society. Series A,.
[21] M. Wulfsohn,et al. A joint model for survival and longitudinal data measured with error. , 1997, Biometrics.
[22] Dimitris Rizopoulos,et al. Joint Models for Longitudinal and Time-to-Event Data: With Applications in R , 2012 .
[23] Joseph G Ibrahim,et al. Basic concepts and methods for joint models of longitudinal and survival data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Yongseok Park,et al. Real‐Time Individual Predictions of Prostate Cancer Recurrence Using Joint Models , 2013, Biometrics.
[25] Dimitris Rizopoulos,et al. A Bayesian semiparametric multivariate joint model for multiple longitudinal outcomes and a time‐to‐event , 2011, Statistics in medicine.
[26] Masahiro Fukuoka,et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Dimitris Rizopoulos,et al. Dynamic Predictions and Prospective Accuracy in Joint Models for Longitudinal and Time‐to‐Event Data , 2011, Biometrics.
[28] Graeme L. Hickey,et al. Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues , 2016, BMC Medical Research Methodology.